Search results
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 5 hours agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 6 hours agoProgression-free survival is how long patients live before their cancer worsens. The company added...
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Pharmaceutical Technology via Yahoo Finance· 1 day agoGlobalData is the parent company of Pharmaceutical Technology. Pfizer is also seeking European...
Stock market today: gloomy start to May ahead of Fed decision
Newsweek· 13 hours agoU.S. futures were down Wednesday morning ahead of a decision by the Federal Reserve on interest...
FDA grants full approval to cervical cancer drug TIVDAK By Investing.com
Investing.com· 2 days agoFood and Drug Administration (FDA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of...
Are Ultra-Processed Foods Really all that Unhealthy?
Scientific American· 5 days agoThe problem, according to this increasingly popular argument, is that we’re eating lots of ultra-processed food or UPF. Traditionally, people used...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoCOPENHAGEN, Denmark; April 30, 2024 – Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
FDA approves Abbott's dissolving stent for leg artery disease By Investing.com
Investing.com· 2 days agoThe U.S. Food and Drug Administration has approved Abbott's Esprit BTK Everolimus Eluting Resorbable...
This Is How Denim Brands Are Paving the Sustainable Way
Elle via Yahoo News· 5 hours agoDenim brands enthusiastically experiment with sustainability, improving processes more and more...
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - G1...
Benzinga· 13 hours ago- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results